The Rise of High-Potency Intermediates highlights a fundamental shift in pharmaceutical manufacturing, where potency-related risks emerge early at the intermediate stage. As oncology and targeted therapies expand, manufacturers must integrate exposure control, impurity strategy, and scalable process design to ensure compliance, safety, and long-term supply reliability.

This article shares real-world insights from two decades of pharmaceutical process development, focusing on how synthesis route design for complex intermediates directly impacts cost, scalability, impurity control, and regulatory compliance.

Explore key pharmaceutical intermediates for cardiovascular drugs, manufacturing requirements, and global market demand supported by regulatory and industry data.